Enteric Viral Panel Gets FDA Clearance
By LabMedica International staff writers Posted on 10 Jan 2019 |
Image: The BD MAX System is a fully automated platform that gives the power to consolidate and standardize a broad range of molecular tests including the BD Max enteric panel (Photo courtesy of Becton Dickinson).
Acute viral gastroenteritis can be contracted by virtually any patient and spread within close community settings such as daycare centers, nursing facilities, and cruise ships.
Norovirus is the most common viral cause and accounts for 19 to 21 million cases of diarrheal illness annually in the USA and 50% of all foodborne diarrheal outbreaks. An enteric panel that detects the viral cause of infectious diarrhea symptoms, including norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus, in all care settings, has been granted 510(k) clearance.
The US Food and Drug Administration (FDA, Silver Springs, MS, USA) has granted the clearance to an enteric suite of molecular tests for the detection of gastrointestinal bacteria, parasitic, or viral pathogens that enables clinicians to perform targeted testing for patients based on their symptoms, health history, or exposure.
The BD Max enteric panel (Becton Dickinson, Franklin Lakes, NJ, USA) can return results in less than 3.5 hours, shortening time to results over traditional test methods and allowing clinicians to more quickly understand the cause of the patient's illness. The enteric panels run on the BD Max system, a fully integrated, automated molecular diagnostics platform that performs nucleic acid extraction and real-time polymerase chain reaction (RT-PCR).
Nikos Pavlidis, MSc, vice president and general manager of molecular diagnostics and women's health for BD, said, “The firm's launch of the enteric viral panel and suite of assays for diagnosing gastrointestinal conditions will provide clinicians with greater flexibility for more efficient and cost-effective patient management.”
Norovirus is the most common viral cause and accounts for 19 to 21 million cases of diarrheal illness annually in the USA and 50% of all foodborne diarrheal outbreaks. An enteric panel that detects the viral cause of infectious diarrhea symptoms, including norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus, in all care settings, has been granted 510(k) clearance.
The US Food and Drug Administration (FDA, Silver Springs, MS, USA) has granted the clearance to an enteric suite of molecular tests for the detection of gastrointestinal bacteria, parasitic, or viral pathogens that enables clinicians to perform targeted testing for patients based on their symptoms, health history, or exposure.
The BD Max enteric panel (Becton Dickinson, Franklin Lakes, NJ, USA) can return results in less than 3.5 hours, shortening time to results over traditional test methods and allowing clinicians to more quickly understand the cause of the patient's illness. The enteric panels run on the BD Max system, a fully integrated, automated molecular diagnostics platform that performs nucleic acid extraction and real-time polymerase chain reaction (RT-PCR).
Nikos Pavlidis, MSc, vice president and general manager of molecular diagnostics and women's health for BD, said, “The firm's launch of the enteric viral panel and suite of assays for diagnosing gastrointestinal conditions will provide clinicians with greater flexibility for more efficient and cost-effective patient management.”
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA